HTB

2005

Volume 6 Number 11/12 November/December 2005

7th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13-16 November 2005, Dublin, Ireland

Monitoring side effects in resource limited countries

Uridine supplement reverses thymidine-induced lipoatrophy

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

Niacin has beneficial effect on lipids but no reduction in abdominal fat

Gluteal implants used to replace lost buttock fat

10th European AIDS Conference, 17-20 November 2005, Dublin, Ireland

Pregnancy studies at EACS

Brazil’s deal with Abbott is challenged in courts

Named-patient access programme available in UK for new protease inhibitor darunavir (TMC114)

Tibotec discontinues TMC125 study C227: phase III studies continue

New Kaletra tablet formulation (meltrex) approved by FDA

GSK closes phase 3 studies of its CCR5 inhibitor aplaviroc and terminates development programme

Schering discontinues phase 2 studies of vicriviroc in treatment naive patients

FDA issues approvable letter for Bioject needle-free injection device

Cost effectiveness of resistance testing for treatment-naive patients

Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)

US pregnancy guidelines updated

European activists denounce pricing increases for HIV drugs as ‘unbearable’

Guidelines for the use of antiretroviral agents in pediatric HIV infection

American Association For The Study of Liver Diseases (AASLD), November 11-15, 2005 San Francisco

Medscape articles and online papers

Community newsletters and journals

HIV inSite Knowledge Base

Amedeo HIV Medicine

Volume 6 Number 11/12 November/December 2005 PDF

Volume 6 Number 10 October 2005

Further Reports from 3rd IAS Conference on AIDS Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24-27 July 2005

Management of hepatitis C and B in HIV-coinfected individuals: an overview of studies presented at the 3rd IAS Conference

Highlights of HIV drug resistance studies presented at the 3rd IAS Conference

GSK stops trials of CCR5 entry inhibitor GW873140 in naive patients

AZT comes off patent: generic versions approved for US market

Depletion of latent HIV-1 reservoir with valproic acid: interesting data but not a cure

Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy

Breast milk, HIV suppression and decreased mother to child transmission

Single dose nevirapine infant prophylaxis to reduce mother to child transmission may have similar efficacy to maternal and infant doses

Pharmacokinetics of nevirapine in HIV positive children receiving Thai fixed dose combination

WHO – Patients for patient safety: call for participants

Does buprenorphine have a role in preventing HIV transmission and treating HIV-infected IDUs?

Medscape articles and online papers

Neurological complications of HIV infection

HIV inSite Knowledge Base

WHO list of essential medicines

Volume 6 Number 10 October 2005 PDF

Volume 6 Number 9 September 2005

3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy

Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS

New drugs in pregnancy: atazanavir; T20

Lopinavir/r use in children less than two years old – promising results despite low plasma levels

Favourable outcomes in children treated with HAART in the MSF programmes

Encouraging results with cut up generic fixed dose combination tablets in Uganda

Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire

Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results

T20 (enfuvirtide) studies presented at Rio

Strategies for salvage therapy

Antiviral activity of foscarnet in salvage patients

Novel strategies with existing drugs

Antiretroviral activity of new and novel agents

Overview of pharmacology studies

Incidence of TB infection despite HAART and treatment in coinfected patients

Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients

Does WHO clinical stage reliably predict who should receive ARV treatment?

Post navigation